NCT00548470View on ClinicalTrials.gov

Varenicline Effects In Schizophrenic Smokers

PHASE4CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

December 31, 2010

Conditions
SchizophreniaTobacco Use DisorderNicotine Dependance
Interventions
DRUG

Varenicline

Varenicline 1-2 mg/day

Trial Locations (1)

10035

Manhattan Psychiatric Center, New York

All Listed Sponsors
collaborator

University of Illinois at Chicago

OTHER

lead

Nathan Kline Institute for Psychiatric Research

OTHER

NCT00548470 - Varenicline Effects In Schizophrenic Smokers | Biotech Hunter | Biotech Hunter